Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Shares in Novo Nordisk fell sharply after the announcement. However, that was likely driven by news that Wegovy and two other semaglutide products – Ozempic and Rybelsus for type 2 diabetes ...

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...